Product
Ramucirumab + Paclitaxel
Aliases
Ramucirumab plus Paclitaxel, standard of care, Standard of care, Standard of Care (1 other aliases)
Name
Ramucirumab
2 clinical trials
1 drug
7 indications
Indication
Stomach CancerIndication
Stomach AdenocarcinomaIndication
Esophageal CancerIndication
Metastatic CancerIndication
Solid TumorIndication
Advanced CancerIndication
non-Hodgkin lymphomaDrug
TiragolumabClinical trial
nextHERIZON: An Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This TreatmentStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Clinical trial
A Phase 1, Dose Escalation Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)Status: Active (not recruiting), Estimated PCD: 2022-02-01